Suchergebnisse - "Shi, Yuankai"

PubPharm (21)

1

Identification of novel prognostic autoantibodies in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone via a high-throughput antigen microarray

enthalten in: Cancer | 2024

von Dai, L. | Chen, H. | Tan, Q. | +14

2

Development and validation of a novel risk stratification model and a survival rate calculator for diffuse large B-cell lymphoma in the rituximab era : a multi-institutional cohort study

enthalten in: Annals of hematology | 2024

von Zhong, Q. | Chen, H. | Chen, D. | +11

3

Long-term outcomes with HLX01 (HanliKang®), a rituximab biosimilar, in previously untreated patients with diffuse large B-cell lymphoma : 5-year follow-up results of the phase 3 HLX01-NHL03 study

enthalten in: BMC cancer | 2024

von Qin, Y. | Song, Y. | Wang, D. | +25

4

Efficacy and safety of PD-1 monoclonal antibody plus rituximab in relapsed/refractory diffuse large B cell lymphoma patients

enthalten in: European journal of haematology | 2023

von Qin, Y. | He, X. | Chen, X. | +8

5

Comparison of efficacy and safety of ripertamab (SCT400) versus rituximab (Mabthera® ) in combination with CHOP in patients with previously untreated CD20-positive diffuse large B-cell lymphoma : A randomized, single-blind, phase III clinical trial

enthalten in: Hematological oncology | 2022

von Shi, Y. | Zhang, Q. | Hong, X. | +32

6

Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma

enthalten in: The New England journal of medicine | 2022

von Wang, M. | Jurczak, W. | Jerkeman, M. | +129

CommentIn: Nat Rev Clin Oncol. 2022 Aug;19(8):494. - PMID 35750854

7

Enhancement of the International prognostic index with β2-microglobulin, platelet count and red blood cell distribution width : a new prognostic model for diffuse large B-cell lymphoma in the rituximab era

enthalten in: BMC cancer | 2022

von Chen, H. | Zhong, Q. | Zhou, Y. | +10

8

Prognostic value of BCL2 and TP53 genetic alterations for diffuse large B-cell lymphoma patients treated with R-CHOP

enthalten in: Cancer biology & medicine | 2021

von Qin, Y. | Chen, H. | Liu, P. | +9

9

The pretreatment platelet count predicts survival outcomes of diffuse large B-cell lymphoma : An analysis of 1007 patients in the rituximab era

enthalten in: Leukemia research | 2021

von Chen, H. | Qin, Y. | Yang, J. | +7

10

Efficacy and safety of obinutuzumab for the first-line treatment of follicular lymphoma : a subgroup analysis of Chinese patients enrolled in the phase III GALLIUM study

enthalten in: Chinese medical journal | 2021

von Hong, X. | Song, Y. | Shi, Y. | +8